FD-combo drugs taken off Indian market
About 40 fixed-dose-combination (FDC) drugs are set to be removed from pharmacies in India, and another 1,300 combinations are to be reviewed, following a recommendation from the drug regulatory authority, reports the Hindustan BusinessLine newspaper.
Four separate lists have been sent by the central Drug Controller General of India to state regulators outlining combination drugs that have been banned or rejected by either of them. This is part of the DCGI's exercise to screen the estimated 30.0 billion-rupee ($738.0 million) FDC market.
On the DCGI's list of 12 banned FDCs are pain-killers, gastrointestinal, orthopedic and central nervous system medicines. State regulators are also set to act on 34 rejected combination drugs, taking them off the market and withdrawing manufacturing licences, a Health Ministry official told Business Line.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze